Key Takeaways
- Clinical Bottom Line
- What Changed in the Last 12 Months
- The Practical Diagnostic Framework
- Where Anti-CdtB and Anti-Vinculin Fit
Clinical Bottom Line
| Clinical Task | Useful Tests | What Not To Do |
|---|---|---|
| Rule out inflammatory disease | Fecal calprotectin or lactoferrin, with CRP depending on the guideline and context. | Do not diagnose IBS-D from symptoms alone when alarm features or abnormal labs are present. |
| Make a positive IBS-D diagnosis | Rome symptom pattern, celiac serology, targeted stool testing, and alarm-feature triage. | Do not call IBS a diagnosis of exclusion that automatically requires colonoscopy. |
| Use emerging IBS biomarkers | Serologic or multi-omic panels may help phenotype selected patients. | Do not use anti-CdtB or anti-vinculin to override guideline-based endoscopy or screening indications. |
What Changed in the Last 12 Months
The recent biomarker literature moved forward, especially with 2025 systematic review data on urinary metabolites, fecal peptidase activity, RAID-IBS, and other proposed diagnostic panels. The signal is interesting. It does not replace the current practice framework.
For a busy gastroenterologist, the useful update is narrower: IBS-D should be diagnosed positively, but the “positive” diagnosis still requires alarm-feature triage and targeted testing. Fecal inflammatory markers remain the most practical tool for separating functional diarrhea from IBD risk in the right patient.
The Practical Diagnostic Framework
Step 1: Confirm the symptom pattern
IBS-D requires recurrent abdominal pain associated with defecation or change in stool frequency or form. Functional diarrhea has chronic loose stools without the same pain-predominant pattern. That distinction matters because treatment goals and patient counseling differ.
Step 2: Screen for alarm features
- GI bleeding, iron deficiency anemia, unintentional weight loss, nocturnal diarrhea, fever, persistent severe symptoms, or abnormal examination.
- New onset after age 45, or any patient due for colorectal cancer screening.
- Family history of colorectal cancer, IBD, or celiac disease.
- Abnormal CBC, albumin, CRP, fecal calprotectin, or fecal lactoferrin.
If any of these are present, do not let a biomarker panel create false reassurance. Investigate the specific risk.
Step 3: Use targeted tests
- Celiac serology is recommended in patients with IBS-D symptoms.
- Fecal calprotectin or fecal lactoferrin helps screen for IBD in chronic watery diarrhea or suspected IBS-D when no alarm features are present.
- Giardia testing is reasonable when exposure risk or compatible symptoms exist.
- Consider bile acid diarrhea testing or an empiric bile acid sequestrant strategy when symptoms fit and local testing is limited.
- Routine broad stool pathogen panels are not needed for every chronic IBS-D presentation.
Where Anti-CdtB and Anti-Vinculin Fit
Anti-CdtB and anti-vinculin are best understood as possible post-infectious IBS-D phenotype markers. They may support a story of symptoms beginning after acute gastroenteritis, but they are not a universal IBS rule-in test and they are not a substitute for alarm-feature evaluation.
The AGA laboratory guideline makes no recommendation for currently available serologic tests for IBS diagnosis. That is the key clinical guardrail. Use these tests cautiously, if at all, and avoid building a practice pathway where a positive proprietary test blocks appropriate colonoscopy, celiac testing, inflammatory marker testing, or age-based screening.
Treatment Selection After Triage
| Phenotype | Reasonable Options | Clinical Note |
|---|---|---|
| Meal-triggered bloating and diarrhea | Dietitian-guided low-FODMAP trial, soluble fiber in selected patients | Stop dietary restriction if it fails. Avoid open-ended elimination diets. |
| Post-infectious IBS-D pattern | Rifaximin, symptom-directed antidiarrheals, gut-brain neuromodulator when pain is prominent | Do not equate a post-infectious marker with active infection. |
| Urgency without dominant pain | Loperamide for stool frequency, bile acid strategy when suspected | Loperamide may help diarrhea but usually does not treat global IBS symptoms. |
| Pain-predominant IBS-D | Tricyclic antidepressant, antispasmodic, behavioral gut-brain therapy | Frame neuromodulators as visceral pain treatment, not as a dismissal of symptoms. |
| Severe IBS-D in selected patients | Eluxadoline or alosetron when appropriate | Check contraindications, including absent gallbladder for eluxadoline. |
How to Apply This in Practice
- Create a one-page IBS-D intake template with Rome symptoms, alarm features, age-based screening status, celiac serology, fecal calprotectin or lactoferrin, and CBC.
- Use colonoscopy when the patient has alarm features, abnormal biomarkers, new-onset symptoms at screening age, or unresolved diagnostic uncertainty.
- When tests support IBS-D, name the diagnosis directly and begin therapy instead of ordering serial low-yield exclusions.
- When symptoms persist, reassess phenotype: bile acid diarrhea, microscopic colitis risk, medication effect, carbohydrate intolerance, pelvic floor disorder, and overlapping anxiety or hypervigilance.
Practice Pitfalls
- Using the phrase “IBS is excluded if fecal calprotectin is below 50.” A low value lowers IBD probability, but it is not a universal exclusion of organic disease.
- Using anti-CdtB or anti-vinculin as a stand-alone diagnostic gate.
- Skipping celiac testing in IBS-D.
- Ordering colonoscopy for every young patient with classic IBS-D and no warning signs.
- Failing to revisit the diagnosis when symptoms evolve, biomarkers become abnormal, or treatment response is poor.
Key Sources
- ACG guideline summary: Management of IBS
- ACG Clinical Guideline full text
- AGA laboratory evaluation of functional diarrhea and IBS-D
- AGA pharmacologic management of IBS-D
- 2025 systematic review and meta-analysis of IBS biomarkers
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: May 3, 2026. This article is intended for physicians and advanced clinicians.
